We are delighted to announce that NHS patients will soon have access to a groundbreaking gene-editing therapy for sickle cell disease—a major milestone in the fight against this painful, life-limiting condition. Approved by NICE, this innovative treatment offers the prospect of a functional cure for eligible patients. For too long, those living with sickle cell have endured chronic pain, frequent hospital admissions, and few treatment options. Now, thanks to advances in gene therapy, there is real hope for a future free from the burden of sickle cell crises. Clinical trials have shown that an impressive 96.6% of patients treated with this one-time therapy achieved a functional cure, with the majority avoiding hospitalisation for years after treatment.
“This groundbreaking treatment offers real hope for people living with sickle cell disease, with the potential to transform lives and dramatically reduce the pain and complications they face. It’s a major step forward in addressing health inequalities and improving outcomes for those affected. We’re excited about the future impact of this revolutionary therapy and what it could mean for patients across the country.”
Here in North Central London, the NCL ICB is already working hard to support those living with sickle cell. Our dedicated community care initiatives and outstanding hospital teams are making a real difference. One shining example is Matilda Asante-Owusu, a Whittington Hospital sickle cell matron recently awarded an MBE for her incredible work supporting patients. With over 36 years in the NHS, Matilda has been instrumental in providing personalised care, establishing vital patient support groups, and ensuring that individuals living with sickle cell receive the attention they deserve.
Looking ahead, we remain committed to:
- Raising awareness of sickle cell and tackling health inequalities
- Enhancing community-based care and improving access to specialist services
- Supporting research and innovation to transform the future of sickle cell treatment
This breakthrough is a moment to celebrate—a clear sign of progress in the fight against sickle cell disease. At the same time, it reaffirms our commitment to ensuring that all patients receive the best possible care and support. We are excited about the futu
re and the potential this revolutionary therapy has to transform lives across our community.